Yuta Yoshida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Yuta Yoshida has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Ippei Matsumoto
Department of Surgery Kindai University Faculty of Medicine Osakasayama Japan
3 shared publications - Keiko Kamei
Division of Hepato‐Biliary‐Pancreatic Surgery, Department of Surgery Kindai University Faculty of Medicine Sakai Osaka Japan
3 shared publications - Atsushi Takebe
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Osaka, Japan
2 shared publications - Chihoko Nobori
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Osaka, Japan
2 shared publications - Masaya Nakano
Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, Kindai University Faculty of Medicine, Sakai, Osaka, Japan
2 shared publications - Takaaki Murase
Department of Surgery, Kindai University Faculty of Medicine, 1-14-1 Mihara-dai, Minami-ku, Sakai, Osaka 590-0197, Japan
2 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Clinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer
Objective: To identify prognostic factors, including preoperative treatment duration, among patients who underwent conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC). Background: While CS has been increasingly adopted for UR-LAPC, optimal perioperative strategies remain controversial. Methods: This multicenter study included 465 UR-LAPC patients who underwent CS following preoperative chemotherapy with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) from 2015 to 2020 at 84 Japanese institutions. Results: Median overall survival (OS) from treatment initiation was 43.8 months with a 5-year survival rate of 37.2%. A prognostic cutoff for preoperative treatment duration was identified at 6.1 months using maximally selected rank statistics. Patients receiving >6 months of preoperative treatment (n=350) demonstrated significantly better OS (50.4 vs. 29.7 mo) and recurrence-free survival (RFS) (15.6 vs. 9.1 mo) compared with those receiving ≤6 months (n=115, both P 6 months, FFX-based regimens, normal tumor markers (CA19-9 and CEA), and a prognostic nutritional index ≥45 before CS. These four preoperative factors enabled clear prognostic stratification: patients with ≥3 factors showed significantly improved survival compared with those with ≤2 factors (HR 0.44, P <0.0001; 5-year OS: 59.8% vs. 26.3%). Conclusions: The combination of four preoperative prognostic factors may enable risk stratification among patients undergoing CS for UR-LAPC. These findings may help inform treatment sequencing and patient selection, although external validation is needed to confirm their generalizability.
- 21 January 2026
- Published by Wolters Kluwer Health in Annals of Surgery
Open AccessClinicopathological Factors on Survival after Conversion Surgery for Unresectable Locally Advanced Pancreatic Cancer
Objective: To identify prognostic factors, including preoperative treatment duration, among patients who underwent conversion surgery (CS) for unresectable locally advanced pancreatic cancer (UR-LAPC). Background: While CS has been increasingly adopted for UR-LAPC, optimal perioperative strategies remain controversial. Methods: This multicenter study included 465 UR-LAPC patients who underwent CS following preoperative chemotherapy with FOLFIRINOX (FFX) or gemcitabine plus nab-paclitaxel (GnP) from 2015 to 2020 at 84 Japanese institutions. Results: Median overall survival (OS) from treatment initiation was 43.8 months with a 5-year survival rate of 37.2%. A prognostic cutoff for preoperative treatment duration was identified at 6.1 months using maximally selected rank statistics. Patients receiving >6 months of preoperative treatment (n=350) demonstrated significantly better OS (50.4 vs. 29.7 mo) and recurrence-free survival (RFS) (15.6 vs. 9.1 mo) compared with those receiving ≤6 months (n=115, both P 6 months, FFX-based regimens, normal tumor markers (CA19-9 and CEA), and a prognostic nutritional index ≥45 before CS. These four preoperative factors enabled clear prognostic stratification: patients with ≥3 factors showed significantly improved survival compared with those with ≤2 factors (HR 0.44, P <0.0001; 5-year OS: 59.8% vs. 26.3%). Conclusions: The combination of four preoperative prognostic factors may enable risk stratification among patients undergoing CS for UR-LAPC. These findings may help inform treatment sequencing and patient selection, although external validation is needed to confirm their generalizability.
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1)
Pancreatic Ischemic Necrosis Caused by Cholesterol Crystal Embolization Following Total Arch Replacement: A Case Report
- 1 January 2026
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 12 (1)
Pancreatic Ischemic Necrosis Caused by Cholesterol Crystal Embolization Following Total Arch Replacement: A Case Report
- Open Access
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1) , cr.24-0058
An Extremely Rare Case of Coexisting Neuroendocrine Carcinoma and Tumor of the Whole Pancreas with Hepatoid Differentiation
INTRODUCTION: Hepatoid carcinoma (HC) is a rare type of malignant tumor that shares similar serological, morphological, and immunohistochemical features with hepatocellular carcinoma. Pancreatic HC exhibits aggressive biological behavior and is classified as pure type, combined type, and mixed type. Unlike the pure type, the combined and mixed types refer to HC with other histological components. While the most common component is the neuroendocrine tumor (NET), no case of coexistence of neuroendocrine carcinoma (NEC) and NET with hepatoid differentiation has been reported. We herein report an extremely rare case of coexisting NEC and NET of the whole pancreas with hepatoid differentiation.CASE PRESENTATION: A 15-year-old woman had epigastric pain and impaired glucose tolerance, without any medical or family history. Computed tomography (CT) revealed a 6.4-cm mass in the pancreatic head, an enhanced mass throughout the pancreas, and a 1.0-cm liver lesion. Positron emission tomography (PET)/CT and somatostatin receptor scintigraphy (SRS) suggested a NET in the pancreatic body and tail, and a NEC in the pancreatic head. Biopsies confirmed NEC in the pancreatic head and liver with possible hepatoid differentiation. The patient underwent combination chemotherapy with carboplatin and etoposide. Due to the partial response achieved with chemotherapy, which led to significant tumor shrinkage on CT and no uptake on PET/CT in the pancreatic head tumor, the patient proceeded with conversion surgery, including a total pancreatectomy with portal vein resection and partial hepatectomy. However, serum α-fetoprotein (AFP) levels rapidly rose, and multiple liver metastases of NEC were detected on CT at 5 months after surgery. Liver metastases worsened despite further chemotherapy. The patient died 10 months after surgery.CONCLUSIONS: We herein present an extremely rare case of coexisting NET and NEC of the whole pancreas with hepatoid differentiation. Due to a remarkable response to chemotherapy, conversion surgery was performed. However, early recurrence of liver metastases accompanied by a rapid increase in serum AFP levels occurred, and the prognosis was poor. Pancreatic HC should be considered when encountering a bulky tumor of the pancreas with elevated serum AFP levels, and further case series and analysis are needed to determine the appropriate treatment strategy.
- 1 January 2025
- Published by Japan Surgical Society in Surgical Case Reports
- Vol. 11 (1) , cr.24-0058
Open AccessAn Extremely Rare Case of Coexisting Neuroendocrine Carcinoma and Tumor of the Whole Pancreas with Hepatoid Differentiation
INTRODUCTION: Hepatoid carcinoma (HC) is a rare type of malignant tumor that shares similar serological, morphological, and immunohistochemical features with hepatocellular carcinoma. Pancreatic HC exhibits aggressive biological behavior and is classified as pure type, combined type, and mixed type. Unlike the pure type, the combined and mixed types refer to HC with other histological components. While the most common component is the neuroendocrine tumor (NET), no case of coexistence of neuroendocrine carcinoma (NEC) and NET with hepatoid differentiation has been reported. We herein report an extremely rare case of coexisting NEC and NET of the whole pancreas with hepatoid differentiation.CASE PRESENTATION: A 15-year-old woman had epigastric pain and impaired glucose tolerance, without any medical or family history. Computed tomography (CT) revealed a 6.4-cm mass in the pancreatic head, an enhanced mass throughout the pancreas, and a 1.0-cm liver lesion. Positron emission tomography (PET)/CT and somatostatin receptor scintigraphy (SRS) suggested a NET in the pancreatic body and tail, and a NEC in the pancreatic head. Biopsies confirmed NEC in the pancreatic head and liver with possible hepatoid differentiation. The patient underwent combination chemotherapy with carboplatin and etoposide. Due to the partial response achieved with chemotherapy, which led to significant tumor shrinkage on CT and no uptake on PET/CT in the pancreatic head tumor, the patient proceeded with conversion surgery, including a total pancreatectomy with portal vein resection and partial hepatectomy. However, serum α-fetoprotein (AFP) levels rapidly rose, and multiple liver metastases of NEC were detected on CT at 5 months after surgery. Liver metastases worsened despite further chemotherapy. The patient died 10 months after surgery.CONCLUSIONS: We herein present an extremely rare case of coexisting NET and NEC of the whole pancreas with hepatoid differentiation. Due to a remarkable response to chemotherapy, conversion surgery was performed. However, early recurrence of liver metastases accompanied by a rapid increase in serum AFP levels occurred, and the prognosis was poor. Pancreatic HC should be considered when encountering a bulky tumor of the pancreas with elevated serum AFP levels, and further case series and analysis are needed to determine the appropriate treatment strategy.
- Open Access
- 27 October 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , 619-630
High Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study
Context: Glucose tolerance worsens after distal pancreatectomy (DP); however, the long-term incidence and factors affecting interindividual variation in this worsening are unclear. Objective: To investigate the changes in diabetes-related traits before and after DP and to clarify the incidence of diabetes and its predictors. Methods: Among 493 registered patients, 117 underwent DP. Among these, 56 patients without diabetes before surgery were included in the study. Glucose and endocrine function were prospectively assessed using a 75-g oral glucose tolerance test preoperatively, 1 month after DP, and every 6 months thereafter for up to 36 months. Pancreatic volumetry was performed using multidetector row computed tomography before and after surgery. Results: Insulin secretion decreased and blood glucose levels worsened after DP. Residual pancreatic volume was significantly associated with the reserve capacity of insulin secretion but not with blood glucose levels or the development of diabetes. Among 56 patients, 33 developed diabetes mellitus. The cumulative incidence of diabetes at 36 months after DP was 74.1%. Multivariate Cox regression analysis showed that impaired glucose tolerance as a preoperative factor as well as a decreased insulinogenic index and impaired glucose tolerance at 1 month postoperatively were identified as risk factors for diabetes following DP. Conclusion: Impaired glucose tolerance and reduced early-phase insulin response to glucose are involved in the development of new-onset diabetes after DP; the latter is an additional factor in the development of diabetes and becomes apparent when pancreatic beta cell mass is reduced after DP.
- 27 October 2023
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 109 (3) , 619-630
Open AccessHigh Incidence of Diabetes Mellitus After Distal Pancreatectomy and Its Predictors: A Long-term Follow-up Study
Context: Glucose tolerance worsens after distal pancreatectomy (DP); however, the long-term incidence and factors affecting interindividual variation in this worsening are unclear. Objective: To investigate the changes in diabetes-related traits before and after DP and to clarify the incidence of diabetes and its predictors. Methods: Among 493 registered patients, 117 underwent DP. Among these, 56 patients without diabetes before surgery were included in the study. Glucose and endocrine function were prospectively assessed using a 75-g oral glucose tolerance test preoperatively, 1 month after DP, and every 6 months thereafter for up to 36 months. Pancreatic volumetry was performed using multidetector row computed tomography before and after surgery. Results: Insulin secretion decreased and blood glucose levels worsened after DP. Residual pancreatic volume was significantly associated with the reserve capacity of insulin secretion but not with blood glucose levels or the development of diabetes. Among 56 patients, 33 developed diabetes mellitus. The cumulative incidence of diabetes at 36 months after DP was 74.1%. Multivariate Cox regression analysis showed that impaired glucose tolerance as a preoperative factor as well as a decreased insulinogenic index and impaired glucose tolerance at 1 month postoperatively were identified as risk factors for diabetes following DP. Conclusion: Impaired glucose tolerance and reduced early-phase insulin response to glucose are involved in the development of new-onset diabetes after DP; the latter is an additional factor in the development of diabetes and becomes apparent when pancreatic beta cell mass is reduced after DP.